FBR announces winners of 9th annual Michael E. DeBakey Journalism Awards

The awards recognize outstanding journalism demonstrating the essential role of humane animal research in medical discoveries and scientific breakthroughs

The Foundation for Biomedical Research (FBR) today announces the winners of the 9th annual Michael E. DeBakey Journalism Awards. The awards, named in honor of FBR's late chairman Dr. Michael E. DeBakey, recognize outstanding journalism that explores the essential role of humane animal research in medical discoveries and scientific breakthroughs.

The 2010 winners are Bill Hudson and Bob Hernandez (WCCO-TV, Minneapolis/St. Paul, Minnesota), Lorna Benson (Minnesota Public Radio), Jim Spencer (Minneapolis Star Tribune), Tim Lloyd (Columbia Missourian) and Emily Singer (Technology Review). The judging panel was composed of both members of the media and the scientific community.  

"We applaud a well-balanced and accurate discussion of animal research," said FBR president Frankie Trull. "The DeBakey awards are a unique opportunity for scientists and the media to converge in celebration of strides made in science and medicine."

An awards dinner to honor the winners will be held on Thursday, June 17, 2010.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy